The abstract is read at the publisher; the summary is JClub's.
KH3 treatment attenuates DOCA+Ang II–induced chronic kidney disease in male mice by reducing HuR upregulation and fibrosis, alongside improved renal function and lower albuminuria.
- Why it matters: HuR is reported to be upregulated in CKD, but its role in hypertensive renal and vascular injury—and whether blocking it can slow progression—was unclear.
- What they did: Male mice with uninephrectomy received DOCA plus Ang II with 1% NaCl and were treated with KH3 or vehicle for 3 weeks; HuR was assessed in circulating exosomes and kidney tissue.
- The result: KH3 lowered albuminuria, improved renal function, reduced kidney hypertrophy and glomerular/tubulointerstitial fibrosis, decreased podocyte/tubular injury and macrophage infiltration, suppressed NF-κB p65, Nox2, AKT phosphorylation, TGFβ1, and Wisp1 signaling, and partially lowered arterial blood pressure.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.